Articles by Katie Kosko
The phase 3 global, multi-center trial included 492 patients with stage IV NSCLC.
Nivolumab plus ipilimumab with chemotherapy also helped patients with brain metastases live longer versus chemotherapy alone.
Researchers used data from the Thoracic Tumors Registry to conduct 2 analyses using artificial intelligence.
The intervention included psychoeducation, relaxation training, and behavioral techniques for managing acute breathlessness.
Researchers addressed the limited data comparing relative outcomes among osimertinib, afatinib, and erlotinib.
The analysis supplements the primary report and shows that selpercatinib may prevent the formation of new CNS metastases.
Researchers uncovered an association between survival and intratumoral Escherichia in patients receiving certain therapies.
Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.
The study included patients who had received a diagnosis of stage IIA-III unresectable NSCLC.
Study investigators say that extended follow-up research on nivolumab consolidation is essential.
The study showed that the detection of ctDNA predicted significantly inferior NSCLC.
A new study showed surprising results about lung cancer screening during the pandemic.
Most patients who received adjuvant osimertinib achieved MRD negativity.
More than half of patients in the study had psychological distress as well as elevated serum cortisol levels.
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
Researchers evaluated primary ambulatory thromboprophylaxis because thrombosis is a leading cause of death in these patients.
A prospective study evaluated if hypercoagulable and inflammatory biomarkers could predict certain outcomes.
Nearly 80% of patients enrolled had epithelioid histology and 65% had an ECOG performance status of 1.
The study showed that patients with certain types of insurance had significantly shorter overall survival.
Certain patients appeared to derive the greatest benefit from the therapy.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.